Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas

A legfontosabb adatok

Ki végzi
Dartmouth-Hitchcock Medical Center
Hol
Boston, Burlington és Lebanon (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
94 fő vett részt
Kezdés
2013. okt. 9.
Befejezés
2025. aug. 25.
A vizsgálat típusa
Megfigyeléses
A regiszteradat frissítve
2025. szeptember 15.
Miért állt le
Study was administratively closed by IRB

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Egyéb feltételek

  • Inclusion/Exclusion Criteria:
  • 18 years of age
  • Brain tumor(s) to be resected for clinical reasons
  • Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV
  • Adequate tissue available for processing as determined by Pathology
  • Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment
  • Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy

Helyszínek itt: Egyesült Államok

  • Massachusetts General HospitalBoston, Egyesült Államok
  • Tufts Medical CenterBoston, Egyesült Államok
  • University of VermontBurlington, Egyesült Államok
  • Dartmouth Hitchcock Medical CenterLebanon, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas
A regiszteradat frissítve
2025. szeptember 15.